Cearvol Diamond X1 vs Otofonix Groove

The Cearvol Diamond X1 is a budget-priced OTC hearing aid that earned a B grade with a SoundScore of 3.7/5 in our lab testing, placing it in the top 45% of OTC devices. At $199, it represents an accessible entry point for those exploring hearing amplification. The Diamond X1's standout performance is in music streaming, scoring 4.1/5—a strong result that sits 2.18 points above the OTC category average. This makes it notably capable for users who prioritize audio entertainment through their hearing devices. Feedback handling is also excellent at 4.5/5, meaning users should experience minimal whistling during normal use. However, speech performance presents limitations. Speech in quiet scores a mixed 2.8/5, and speech in noise registers at 1.7/5. While both metrics technically sit above category averages (+0.03 and +0.22 points respectively), they remain low in absolute terms—important context for anyone prioritizing conversation clarity. Own-voice comfort is another weakness, scoring 1.7/5, which is 0.81 points below the category average and may affect how natural users sound to themselves. The Diamond X1 is best suited for budget-conscious consumers who value music streaming quality and aren't heavily reliant on challenging listening environments. Those who prioritize speech understanding in noise or natural own-voice perception may want to consider alternatives in this price range, such as the higher-scoring Elehear Beyond or Apple AirPods Pro 2.

The Otofonix Groove is a behind-the-ear prescription hearing aid priced at $795, earning a C grade with a SoundScore of 2.7/5 in our lab testing. This rechargeable BTE ranks #38 of 39 devices in the prescription hearing aid category, placing it in the bottom 5% of its class. In our testing, the Groove demonstrated excellent feedback handling at 5.0/5, scoring 0.28 points above the category average. This represents a genuine strength, with the device maintaining stability during our standardized challenge motions. However, speech performance was significantly limited, with speech in quiet scoring 1.0/5 (2.40 points below the category average of 3.40) and speech in noise also at 1.0/5 (1.11 points below average). Music streaming was not functional in our tests, scoring 0.0/5 against a category average of 2.76. Own-voice comfort also fell well below typical prescription hearing aid performance at 0.4/5, which is 2.30 points below the category average. At this price point, several lower-cost alternatives delivered stronger overall performance in our testing. Consumers seeking value in the prescription category may want to explore other options, though those requiring robust feedback control in a rechargeable BTE format may find the Groove's stability noteworthy despite its other limitations.